
  
    
      
        
        What_WP holds_VBZ cells_NNS together_RB or_CC connects_VBZ them_PRP with_IN the_DT extracellular_NN matrix—and_NN what_WP
        happens_VBZ when_WRB these_DT interactions_NNS break_VBP down—is_NNS one_CD of_IN the_DT keys_NNS to_TO determining_VBG how_WRB tumors_NNS
        metastasize_NN ._. One_CD group_NN of_IN compounds—integrins—are_NN a_DT central_JJ part_NN of_IN these_DT interactions_NNS ._. Not_RB
        only_RB do_VBP integrins_NNS play_VBP a_DT part_NN in_IN cell–cell_NN and_CC cell–matrix_NN adhesion_NN ,_, but_CC they_PRP also_RB are_VBP
        involved_VBN in_IN signal_NN transduction_NN (_( the_DT method_NN by_IN which_WDT a_DT cell_NN relays_NNS information_NN from_IN
        receptor_NN binding_JJ to_TO cellular_JJ response_NN )_) and_CC in_IN triggering_VBG cell_NN death_NN by_IN linking_VBG to_TO other_JJ
        molecules_NNS ._. One_CD such_JJ member_NN of_IN this_DT receptor_NN family_NN is_VBZ the_DT avß_NN 3_CD integrin_NN ,_, which_WDT is_VBZ expressed_VBN
        on_IN both_DT the_DT tumor_NN cells_NNS and_CC the_DT new_JJ vasculature_NN of_IN various_JJ tumors_NNS ,_, including_VBG melanomas_NNS ._.
        avß_NN 3_CD integrin_NN has_VBZ a_DT role_NN in_IN cell_NN migration_NN and_CC extravasation_NN ,_, which_WDT occurs_VBZ during_IN
        metastasis_NNS ,_, and_CC also_RB in_IN angiogenesis—the_NN development_NN of_IN new_JJ blood_NN vessels_NNS that_WDT are_VBP
        essential_JJ for_IN the_DT growth_NN of_IN tumors_NNS ._. These_DT blood_NN vessels_NNS are_VBP the_DT target_NN for_IN one_CD class_NN of_IN
        anti-cancer_JJ drugs—angiogenesis_NNS inhibitors_NNS ._. Molecules_NNP that_DT bind_NN to_TO avß_NN 3_CD integrin_NN have_VBP also_RB
        been_VBN used_VBN to_TO target_VB therapeutic_JJ compounds_NNS to_TO tumors_NNS :_: compounds_NNS that_WDT antagonize_VB this_DT
        integrin_NN can_MD lead_VB to_TO apoptosis_NNS (_( programmed_VBN cell_NN death_NN )_) of_IN cells_NNS that_WDT express_VBP it_PRP ._.
        Haubner_NNP and_CC colleagues_NNS ,_, the_DT authors_NNS of_IN a_DT paper_NN in_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, have_VBP previously_RB developed_VBN a_DT fluorine-labeled_JJ peptide_NN ,_, [_NN
        18_CD F_NN ]_NN Galacto-_NNP RGD_NNP ,_, that_WDT has_VBZ a_DT high_JJ affinity_NN for_IN avß_NN 3_CD integrin_NN ._. [_NN
        18_CD F_NN ]_NN Galacto-_NNP RGD_NNP has_VBZ many_JJ of_IN the_DT features_NNS essential_JJ for_IN a_DT tracer_NN :_: it_PRP is_VBZ
        specifically_RB accumulated_VBN by_IN tumors_NNS that_WDT express_VBP avß_NN 3_CD integrin_NN ,_, it_PRP is_VBZ efficiently_RB eliminated_VBN
        by_IN the_DT kidneys_NNS ,_, and_CC it_PRP is_VBZ stable_JJ in_IN vitro_NN and_CC in_IN vivo_NN ._.
        In_IN the_DT research_NN paper_NN in_IN 
        PLoS_NNP Medicine_NNP ,_, Haubner_NNP and_CC colleagues_NNS take_VBP the_DT development_NN of_IN the_DT
        compound_NN further_RB towards_IN clinical_JJ application_NN ._. First_LS ,_, in_IN a_DT mouse_NN with_IN human_JJ melanoma_NN they_PRP
        used_VBD highly_RB sensitive_JJ positron_NN emission_NN tomography_NN (_( PET_NNP )_) scanning_VBG to_TO show_VB not_RB only_RB that_IN the_DT
        level_NN of_IN uptake_NN of_IN integrin_NN was_VBD specific_JJ for_IN the_DT tumor_NN ,_, but_CC also_RB that_IN the_DT uptake_NN was_VBD in_IN
        direct_JJ proportion_NN to_TO the_DT amount_NN of_IN avß_NN 3_CD expressed_VBD ,_, thus_RB potentially_RB allowing_VBG quantification_NN
        of_IN receptor_NN expression_NN ;_: however_RB ,_, larger_JJR tumors_NNS showed_VBD a_DT poorer_JJR correlation_NN ,_, possibly_RB
        because_IN of_IN the_DT presence_NN of_IN necrotic_JJ areas_NNS that_WDT do_VBP not_RB express_VB the_DT integrin_NN ._.
        In_IN humans_NNS ,_, this_DT picture_NN was_VBD a_DT little_JJ less_RBR clear_JJ ;_: in_IN a_DT small_JJ study_NN of_IN patients_NNS with_IN
        tumors_NNS including_VBG melanoma_NN ,_, the_DT authors_NNS found_VBD a_DT good_JJ deal_NN of_IN difference_NN between_IN patients_NNS in_IN
        the_DT uptake_NN of_IN the_DT marker_NN by_IN tumor_NN cells_NNS and_CC the_DT corresponding_JJ tumor_NN vasculature_NN ._. However_RB ,_,
        there_EX was_VBD good_JJ correlation_NN between_IN the_DT tracer_NN uptake_NN and_CC conventional_JJ staining_VBG for_IN the_DT
        integrin_NN by_IN immunohistochemistry—again_NN suggesting_VBG that_IN the_DT marker_NN is_VBZ truly_RB reflecting_VBG the_DT
        in_IN vivo_NN level_NN of_IN the_DT integrin_NN ._.
        What_WP do_VBP these_DT results_NNS mean_VBP for_IN clinical_JJ applications_NNS ?_. As_RB well_RB as_IN identifying_VBG tumors_NNS that_WDT
        express_VBP this_DT marker_NN ,_, this_DT approach_NN might_MD also_RB offer_VB a_DT noninvasive_JJ way_NN to_TO assess_VB the_DT degree_NN
        of_IN new_JJ vessel_NN formation_NN in_IN tumors_NNS ._. The_DT approach_NN could_MD provide_VB important_JJ information_NN for_IN
        planning_NN and_CC monitoring_VBG anti-angiogenic_JJ therapies_NNS targeting_VBG this_DT integrin_NN and_CC could_MD reveal_VB
        the_DT involvement_NN and_CC role_NN of_IN this_DT integrin_NN in_IN metastatic_JJ and_CC angiogenic_JJ processes_NNS in_IN various_JJ
        diseases_NNS ._.
      
    
  
